Last updated: September 8, 2026
Dermatophagoides farinae is a house-dust-mite allergen used in subcutaneous immunotherapy extracts and sublingual immunotherapy tablets. It is not a conventional single-molecule drug. The commercial market is divided between physician-administered allergen extracts, mainly sold as compounded or standardized immunotherapy products, and branded sublingual tablets such as Odactra in the United States and Acarizax in Europe.
The market has durable demand because house-dust-mite sensitization is widespread, symptoms are chronic, and treatment can modify the underlying allergic response rather than provide only short-term symptom relief. Financial growth is constrained by long treatment courses, adherence challenges, product-specific reimbursement, manufacturing standardization, and competition from antihistamines, intranasal corticosteroids, biologic therapies for severe asthma, and environmental controls.
What is Dermatophagoides farinae whole-body allergen extract?
Dermatophagoides farinae is a house-dust-mite species. The phrase “insects, whole body” is a regulatory or product-class descriptor for an allergenic extract and should not be interpreted as a conventional insect-derived pharmaceutical ingredient. D. farinae is an arachnid, not an insect.
Whole-body mite extracts contain a mixture of allergenic proteins and other biological material derived from the mite. Important mite allergens include Der f 1 and Der f 2. Extract composition depends on the source material, culture conditions, purification process, potency assay, and formulation.
| Product type |
Active material |
Administration |
Main commercial use |
| Subcutaneous immunotherapy extract |
D. farinae extract, often combined with other allergens |
Injection in an allergy clinic |
Personalized allergy immunotherapy |
| Sublingual tablet |
Standardized D. farinae and D. pteronyssinus allergens |
Daily tablet at home after supervised first dose |
House-dust-mite allergic rhinitis, with or without conjunctivitis |
| Diagnostic extract |
Mite allergen extract |
Skin-prick or intradermal testing |
Identification of sensitization |
| Research or component-resolved product |
Individual mite proteins or recombinant allergens |
Clinical or research use |
Biomarker and precision-allergy applications |
FDA-regulated allergenic extracts are biologic products overseen by the Center for Biologics Evaluation and Research. They are distinct from conventional small-molecule drugs and do not follow the same generic-substitution model as tablets such as antihistamines.
Which products contain Dermatophagoides farinae allergens?
The most commercially significant standardized product is Odactra, a sublingual immunotherapy tablet marketed in the United States. It contains allergens from both D. farinae and D. pteronyssinus. The product was developed by ALK and commercialized in the U.S. through Merck under a licensing arrangement. FDA approved Odactra in 2017 for house-dust-mite-induced allergic rhinitis, with or without conjunctivitis, in adults ages 18 through 65. The indicated age range was later expanded to include adolescents from age 12.[1]
In Europe and other markets, ALK markets Acarizax, a house-dust-mite sublingual tablet based on the same broad therapeutic concept. Product indications and age ranges vary by country.
Physician-administered D. farinae extracts are supplied by specialist allergen manufacturers, including Stallergenes Greer, Jubilant HollisterStier and other regional producers. These products are commonly used in customized subcutaneous immunotherapy mixtures. Unlike Odactra, they are not generally sold as a single standardized retail prescription with a uniform national market price.
How large is the Dermatophagoides farinae market?
No major manufacturer reports revenue specifically for D. farinae whole-body extract. Financial analysis therefore requires separating the market into three layers:
- The global allergen immunotherapy market.
- The house-dust-mite immunotherapy segment.
- The D. farinae ingredient and extract component.
Public company disclosures generally report allergy-immunotherapy revenue by product family or geography, not by mite species. U.S. revenue for Odactra is not separately disclosed by Merck. ALK reports broader allergy-immunotherapy performance rather than a standalone D. farinae figure.[2]
The commercial market has four principal revenue pools:
| Revenue pool |
Economic profile |
Growth outlook |
| Sublingual mite tablets |
Branded prescription pricing and recurring daily use |
Strongest product-level growth potential |
| Subcutaneous extracts |
Lower unit economics but broad physician use |
Stable, with gradual expansion |
| Allergy diagnostics |
Ancillary revenue linked to immunotherapy initiation |
Moderate |
| Manufacturing and licensing |
Potency-controlled biological production and supply contracts |
Concentrated among specialist suppliers |
The sublingual segment has the clearest route to premium pricing because it offers standardized dosing, home administration, and a defined label. Subcutaneous extracts have broader allergen coverage and can be tailored to the patient, but their economics are affected by clinic capacity, compounding labor, injection schedules and reimbursement.
What is driving market growth?
Rising allergic rhinitis prevalence
House-dust-mite allergy is a persistent driver of allergic rhinitis and asthma in humid indoor environments. Unlike seasonal pollen, mites can trigger symptoms throughout the year. Patients with perennial symptoms are more likely to require continuous therapy and may be candidates for disease-modifying immunotherapy.
Greater use of disease-modifying treatment
Antihistamines and intranasal corticosteroids control symptoms but do not induce allergen tolerance. Immunotherapy is intended to alter the immune response over a multiyear course. This clinical distinction supports premium pricing for sublingual tablets and specialist-administered injections.
Expansion of at-home dosing
Sublingual tablets shift part of treatment from the clinic to the home. The first dose is administered under medical supervision because of the risk of systemic allergic reactions. Subsequent dosing can occur at home, which reduces visit frequency and increases geographic access.
Improved diagnostic segmentation
Component-resolved diagnostics can identify sensitization to Der f 1, Der f 2 and related mite allergens. Greater diagnostic precision could improve patient selection, but it can also narrow the population eligible for a particular extract or tablet.
Unmet need in asthma
House-dust-mite sensitization is associated with allergic asthma. Odactra’s U.S. label includes a warning that it is not indicated for the immediate relief of acute bronchospasm or asthma exacerbation. Treatment selection is therefore linked to disease severity and asthma control rather than allergy symptoms alone.[1]
What limits commercial expansion?
Adherence is the main commercial constraint. Sublingual immunotherapy requires daily dosing for multiple years, while symptom improvement may take months. Discontinuation reduces lifetime revenue per patient and limits the treatment’s real-world effectiveness.
Subcutaneous immunotherapy faces a different bottleneck: administration requires repeated office visits. Shortage of allergists, reimbursement restrictions and clinic staffing limit capacity.
Safety management also affects adoption. Sublingual tablets carry risks of oral and systemic allergic reactions, including anaphylaxis. Prescribers must provide epinephrine and counsel patients on emergency use. Patients with uncontrolled asthma, certain eosinophilic esophageal disorders or relevant contraindications may not be eligible.[1]
Environmental interventions compete with immunotherapy. Mattress encasements, humidity control, vacuuming and integrated pest-management approaches can reduce exposure. These measures are rarely complete substitutes for immunotherapy but can lower drug demand among cost-sensitive patients.
How does D. farinae immunotherapy compare with competing treatments?
| Treatment |
Primary advantage |
Primary limitation |
Financial effect |
| Oral antihistamines |
Low cost and rapid symptom relief |
Does not modify disease |
High volume, low revenue per patient |
| Intranasal corticosteroids |
Strong rhinitis control |
Requires regular use; local adverse effects |
Large generic competition |
| Leukotriene modifiers |
Useful in selected patients |
Less effective for many rhinitis patients |
Limited pricing power |
| Subcutaneous immunotherapy |
Customizable and potentially disease-modifying |
Clinic visits and injection risks |
Recurring specialist revenue |
| Sublingual mite tablets |
Standardized dosing and home administration |
Long treatment duration and adherence burden |
Premium branded pricing |
| Anti-IgE and other biologics |
Effective for severe allergic disease |
High cost and narrow eligibility |
High revenue per patient, smaller population |
| Environmental control |
No systemic drug exposure |
Variable effectiveness and adherence |
Low pharmaceutical revenue |
Sublingual mite tablets compete most directly with subcutaneous immunotherapy, while biologics compete for patients with severe asthma or multiple allergic diseases. The products are not fully interchangeable because they target different severity groups and treatment settings.
What is the FDA regulatory status?
Odactra is FDA-approved as a sublingual allergen immunotherapy tablet for house-dust-mite-induced allergic rhinitis, with or without conjunctivitis, in patients within the approved age range. It contains standardized allergens from D. farinae and D. pteronyssinus.[1]
D. farinae extracts used for injection and diagnosis are regulated as allergenic products. Standardization and potency control are central regulatory issues because extracts are complex biological mixtures. Product comparability is more difficult than for a chemically synthesized active ingredient.
The FDA’s allergenic-extract framework includes manufacturer controls, source-material controls, potency testing, labeling requirements and manufacturing standards. For whole-body extracts, lot consistency and the relationship between measured potency and clinical activity are commercially important.[3]
What patents protect D. farinae immunotherapy products?
Protection is generally distributed across several categories rather than a single species-specific patent:
- Sublingual tablet composition.
- Allergen dose and ratio.
- Tablet disintegration and mucosal delivery.
- Treatment methods for dust-mite allergic rhinitis.
- Patient-selection criteria.
- Manufacturing and standardization methods.
- Combination therapy involving D. farinae and D. pteronyssinus.
Odactra is a biologic allergen product, so its competitive position depends on regulatory exclusivity, formulation patents, manufacturing know-how and clinical data. It does not fit neatly into the conventional small-molecule Orange Book framework. Biological product information is generally evaluated through FDA biologics records and, where applicable, the Purple Book rather than treating the product as a traditional Orange Book generic reference product.[4]
The most important barriers to entry are likely to be clinical comparability, potency standardization, manufacturing validation and reimbursement, rather than only the expiration of a single composition patent.
Are there Paragraph IV challenges or generic-entry threats?
A conventional Paragraph IV challenge is associated with an abbreviated new drug application and Orange Book-listed patents. That pathway is not the primary competitive model for a complex allergen immunotherapy biologic.
Potential entrants could pursue:
- A biologics license application.
- A product-specific allergenic-extract pathway.
- A different sublingual formulation.
- A physician-administered extract with a separate clinical and manufacturing profile.
- A biosimilar-like or interchangeable strategy where legally and scientifically appropriate.
The market risk is therefore more likely to arise from competing products, label expansion and physician substitution than from a near-term conventional generic launch. Sublingual competitors would still need to establish clinical performance, dose equivalence or a clinically credible benefit-risk profile.
What licensing deals affect the market?
ALK developed and owns significant intellectual property and product expertise in house-dust-mite sublingual immunotherapy. Merck commercialized Odactra in the United States under a collaboration with ALK. The relationship gave ALK access to Merck’s U.S. commercial infrastructure while allowing Merck to participate in the allergy-immunotherapy market without developing the underlying tablet platform internally.[5]
The financial consequences are typical of a licensed specialty product:
- ALK retains exposure to product economics and technology value.
- Merck gains U.S. commercialization rights and an established regulatory asset.
- Reported revenue is divided between product sales, collaboration economics and geographic rights.
- Public disclosures do not provide a clean D. farinae-specific revenue line.
What is the financial trajectory?
The financial trajectory is likely to differ by product class.
Sublingual tablets
The outlook is positive but gradual. Revenue depends on new patient starts, persistence beyond the first year, reimbursement, prescriber familiarity and geographic expansion. The products have high potential lifetime value because treatment is intended to continue for approximately three years, but early discontinuation can materially reduce realized revenue.
Injectable extracts
Injectable extracts should remain commercially durable because allergists use them for polysensitized patients and can combine multiple allergens in one treatment program. Revenue growth is likely to track allergy prevalence, physician capacity and clinic utilization rather than rapid branded-drug expansion.
Manufacturing suppliers
Specialist manufacturers have defensible positions where they control validated mite colonies, extraction processes, reference standards and potency assays. Manufacturing failures, raw-material variability or supply interruptions can create disproportionate commercial risk because replacement suppliers require regulatory and clinical qualification.
Investor exposure
D. farinae exposure is usually indirect. Relevant companies may report revenue from broader portfolios covering pollen, molds, venom, food allergens and respiratory products. Investors should avoid attributing total allergy-immunotherapy revenue to house-dust-mite products without a species-level disclosure.
What generic launch scenarios exist?
| Scenario |
Probability profile |
Market effect |
| Direct low-cost generic tablet |
Low relative to conventional drugs |
Requires complex regulatory and potency equivalence work |
| Competing branded mite tablet |
More plausible |
Pressures price, physician loyalty and payer coverage |
| Expanded injectable extract competition |
Ongoing |
Limits pricing for standardized extracts |
| Biosimilar-style product |
Dependent on regulatory precedent |
Could reduce premium pricing if interchangeability is established |
| Continued incumbent dominance |
Plausible |
Supported by manufacturing, clinical and commercial barriers |
The most credible competitive threat is a differentiated branded immunotherapy product, not an immediate tablet generic. A rival could compete through a broader age label, improved adherence, lower dosing frequency, superior reimbursement or better evidence in asthma-related populations.
Key Takeaways
- D. farinae is a house-dust-mite allergen used in allergen extracts and sublingual immunotherapy.
- Odactra is the leading U.S. branded product containing D. farinae and D. pteronyssinus allergens.
- Acarizax is the corresponding major ALK product in several non-U.S. markets.
- The ingredient is not a separately reported financial market; company disclosures generally aggregate house-dust-mite or allergy-immunotherapy revenue.
- Sublingual tablets have higher pricing power, while injectable extracts have broader customization and durable specialist use.
- Treatment duration, adherence, reimbursement and clinic capacity are the main commercial constraints.
- Manufacturing standardization and biological potency control create meaningful entry barriers.
- Conventional Paragraph IV generic entry is less relevant than branded competition, biologics regulation and formulation or manufacturing challenges.
- Market growth is likely to be steady rather than explosive, with the strongest opportunity in standardized, reimbursed, home-administered immunotherapy.
FAQs
Is Dermatophagoides farinae an insect allergen?
No. D. farinae is a house-dust-mite species and therefore an arachnid. “Whole body” refers to the source material used to produce the allergenic extract.
Does Odactra contain only Dermatophagoides farinae?
No. Odactra contains standardized allergens from both D. farinae and D. pteronyssinus.
Is Dermatophagoides farinae extract a biologic drug?
It is regulated as an allergenic biological product when manufactured for diagnostic or immunotherapeutic use. Its regulatory treatment differs from that of conventional small-molecule medicines.
Can D. farinae immunotherapy replace antihistamines?
It can reduce the underlying allergic response over time, but it is not an immediate rescue treatment. Many patients continue symptom-control medicines during the immunotherapy course.
What is the main investment risk for mite-immunotherapy products?
The primary risks are poor long-term adherence, reimbursement limits, clinic capacity constraints, safety-related prescribing barriers and competition from other immunotherapies or severe-asthma biologics.
References
- U.S. Food and Drug Administration. (2024). Odactra prescribing information. https://www.accessdata.fda.gov
- ALK-Abelló A/S. (2024). Annual report 2023. https://www.alk.net
- U.S. Food and Drug Administration. (2007). Points to consider in the characterization of allergenic extracts. Center for Biologics Evaluation and Research. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Merck & Co., Inc. (2014). Merck to commercialize ALK’s house dust mite sublingual allergy immunotherapy tablet in the United States. https://www.merck.com
